European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies

被引：353

作者：

Gossec, L. ^{[1
,2
]}

Smolen, J. S. ^{[3
,4
]}

Gaujoux-Viala, C. ^{[5
,6
]}

Ash, Z. ^{[7
,8
]}

Marzo-Ortega, H. ^{[7
,8
]}

van der Heijde, D. ^{[9
]}

FitzGerald, O. ^{[10
,11
]}

Aletaha, D. ^{[3
]}

Balint, P. ^{[12
]}

Boumpas, D. ^{[13
]}

Braun, J. ^{[14
]}

Breedveld, F. C. ^{[9
]}

Burmester, G. ^{[15
]}

Canete, J. D. ^{[16
,17
]}

de Wit, M. ^{[18
]}

Dagfinrud, H. ^{[19
,20
]}

de Vlam, K. ^{[21
]}

Dougados, M. ^{[2
]}

Helliwell, P. ^{[7
]}

Kavanaugh, A. ^{[22
]}

Kvien, T. K. ^{[19
,20
]}

Landewe, R. ^{[23
]}

Luger, T. ^{[24
]}

Maccarone, M. ^{[25
]}

McGonagle, D. ^{[7
,8
]}

McHugh, N. ^{[26
]}

McInnes, I. B. ^{[27
]}

Ritchlin, C. ^{[28
]}

Sieper, J. ^{[29
]}

Tak, P. P. ^{[30
]}

Valesini, G. ^{[31
]}

Vencovsky, J. ^{[32
]}

Winthrop, K. L. ^{[33
]}

Zink, A. ^{[15
,34
]}

Emery, P. ^{[7
,8
]}

机构：

[1] Hop Cochin, APHP, Rheumatol Dept B, Serv Rhumatol B, F-75014 Paris, France

[2] Paris Descartes Univ, Paris, France

[3] Med Univ Vienna, Div Rheumatol, Dept Med 3, Vienna, Austria

[4] Hietzing Hosp, Dept Med 2, Vienna, Austria

[5] Univ Paris 06, Paris, France

[6] Hop La Pitie Salpetriere, Dept Rheumatol, Paris, France

[7] Univ Leeds, Sect Musculoskeletal Dis, Leeds Inst Mol Med, Leeds, W Yorkshire, England

[8] Leeds Teaching Hosp Trust, NIHR Leeds Musculoskeletal Biomed Res Unit, Leeds, W Yorkshire, England

[9] Leiden Univ, Med Ctr, Dept Rheumatol, Leiden, Netherlands

[10] Univ Coll Dublin, Conway Inst, Dublin, Ireland

[11] St Vincents Univ Hosp, Dept Rheumatol, Dublin 4, Ireland

[12] Natl Inst Rheumatism & Physiotherapy, Rheumatol Dept 3, Budapest, Hungary

[13] Univ Crete, Fac Med, Iraklion, Greece

[14] Ruhr Univ Bochum, Rheumazentrum Ruhrgebiet, Bochum, Germany

[15] Charite, Dept Rheumatol & Clin Immunol, D-13353 Berlin, Germany

[16] Hosp Clin Barcelona, Arthrit Unit, Dept Rheumatol, Barcelona, Spain

[17] IDIBAPS, Barcelona, Spain

[18] PARE, Zurich, Switzerland

[19] Diakonhjemmet Hosp, Dept Rheumatol, Oslo, Norway

[20] Univ Oslo, Fac Med, Oslo, Norway

[21] Univ Hosp, Dept Rheumatol, Louvain, Belgium

[22] Univ Calif San Diego, Div Rheumatol, San Diego, CA 92103 USA

[23] Univ Hosp Maastricht, Dept Internal Med Rheumatol, Maastricht, Netherlands

[24] Univ Hosp Munster, Dept Dermatol, Munster, Germany

[25] PE Pso POF Pan European Psoriasis Patients Org Fo, ADI PSO Assoc Difesa Psorias, Rome, Italy

[26] Royal Natl Hosp Rheumat Dis, Dept Rheumatol, Bath BA1 1RL, Avon, England

[27] Univ Glasgow, Inst Infect Immun & Inflammat, Glasgow, Lanark, Scotland

[28] Univ Rochester, Med Ctr, Allergy Immunol & Rheumatol Div, Rochester, NY 14642 USA

[29] Charite, Berlin, Germany

[30] Univ Amsterdam, Acad Med Ctr, Div Clin Immunol & Rheumatol, NL-1105 AZ Amsterdam, Netherlands

[31] Univ Roma La Sapienza, Dept Internal Med, Rheumatol Unit, Rome, Italy

[32] Inst Rheumatol, Prague, Czech Republic

[33] Oregon Hlth & Sci Univ, Dept Infect Dis Publ Hlth & Prevent Med, Portland, OR 97201 USA

[34] German Rheumatism Res Ctr, Berlin, Germany

来源：

ANNALS OF THE RHEUMATIC DISEASES | 2012年 / 71卷 / 01期

关键词：

ASAS CONSENSUS STATEMENT; LONG-TERM TREATMENT; DOUBLE-BLIND; CONTROLLED-TRIAL; ADALIMUMAB EFFECTIVENESS; EULAR RECOMMENDATIONS; STANDING-COMMITTEE; COX-2; INHIBITORS; TASK-FORCE; METHOTREXATE;

D O I：

10.1136/annrheumdis-2011-200350

中图分类号：

R5 [内科学];

学科分类号：

100201 [内科学];

摘要：

Background Psoriatic arthritis (PsA) is a clinically heterogeneous disease. Clear consensual treatment guidance focused on the musculoskeletal manifestations of PsA would be advantageous. The authors present European League Against Rheumatism (EULAR) recommendations for the treatment of PsA with systemic or local (non-topical) symptomatic and disease-modifying antirheumatic drugs (DMARD). Methods The recommendations are based on evidence from systematic literature reviews performed for non-steroidal anti-inflammatory drugs (NSAID), glucocorticoids, synthetic DMARD and biological DMARD. This evidence was discussed, summarised and recommendations were formulated by a task force comprising 35 representatives, and providing levels of evidence, strength of recommendations and levels of agreement. Results Ten recommendations were developed for treatment from NSAID through synthetic DMARD to biological agents, accounting for articular and extra-articular manifestations of PsA. Five overarching principles and a research agenda were defined. Conclusion These recommendations are intended to provide rheumatologists, patients and other stakeholders with a consensus on the pharmacological treatment of PsA and strategies to reach optimal outcomes, based on combining evidence and expert opinion. The research agenda informs directions within EULAR and other communities interested in PsA.

引用

页码：4 / 12

页数：9

共 80 条

[1]

Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial [J].

Antoni, C ;

Krueger, GG ;

de Vlam, K ;

Birbara, C ;

Beutler, A ;

Guzzo, C ;

Zhou, B ;

Dooley, LT ;

Kavanaugh, A .

ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 (08) :1150-1157

[2]

Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis - Results from the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT) [J].

Antoni, CE ;

Kavanagh, A ;

Kirkham, B ;

Tutuncu, Z ;

Burmester, GR ;

Schneider, U ;

Furst, DE ;

Molitor, J ;

Keystone, E ;

Gladman, D ;

Manger, B ;

Wassenberg, S ;

Weier, R ;

Wallace, DJ ;

Weisman, MH ;

Kalden, JR ;

Smolen, J .

ARTHRITIS AND RHEUMATISM, 2005, 52 (04) :1227-1236

[3]

Antoni CE, 2008, J RHEUMATOL, V35, P869

[4]

Ash ZR., Ann Rheum Dis

[5]

BLACK RL, 1964, JAMA-J AM MED ASSOC, V189, P743

[6]

Cardiovascular and gastrointestinal effects of COX-2 inhibitors and NSAIDs: achieving a balance [J].

Borer, JS ;

Simon, LS .

ARTHRITIS RESEARCH & THERAPY, 2005, 7 (Suppl 4) :S14-S22

[7]

First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis [J].

Braun, J ;

Davis, J ;

Dougados, M ;

Sieper, J ;

van der Linden, S ;

van der Heijde, D .

ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 (03) :316-320

[8]

International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis [J].

Braun, J ;

Pham, T ;

Sieper, J ;

Davis, J ;

van der Linden, S ;

Dougados, M ;

van der Heijde, D .

ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 (09) :817-824

[9]

Criteria, Frequency, and Duration of Clinical Remission in Psoriatic Arthritis Patients with Peripheral Involvement Requiring Second-line Drugs [J].

Cantini, Fabrizio ;

Niccoli, Laura ;

Nannini, Carlotta ;

Cassara, Emanuele ;

Pasquetti, Paolo ;

Olivieri, Ignazio ;

Salvarani, Carlo .

JOURNAL OF RHEUMATOLOGY, 2009, 36 :78-80

[10]

Clark CM, 1999, BRIT J DERMATOL, V141, P279

← 1 2 3 4 5 6 7 8 →